Year:
2015
Region / City:
Australia
Theme:
Oncology
Document Type:
Pharmaceutical Submission
Organization / Institution:
Department of Human Services
Author:
Not specified
Target Audience:
Medical professionals, prescribers
Period of Validity:
Ongoing
Approval Date:
November 2015
Date of Amendments:
Not specified
Treatment Phase:
Initial and Continuing
Condition:
Metastatic Castration-Resistant Prostate Cancer
PBS Indication:
Castration-resistant metastatic carcinoma of the prostate
Clinical Criteria:
Patients who have not received prior docetaxel treatment
Administrative Advice:
Queries directed to the Department of Human Services
Price:
$3,701.18 for maximum quantity
Proprietary Name and Manufacturer:
Xtandi, Astellas Pharma
Category / Program:
General Schedule (Code GE)
Prescriber Type:
Medical practitioners, nurse practitioners, optometrists, midwives
Treatment Criteria:
Not to be used in combination with chemotherapy
Context:
A pharmaceutical submission for the inclusion of enzalutamide on the PBS for asymptomatic metastatic castration-resistant prostate cancer patients who have not previously had docetaxel treatment.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:
-
Buy Crypto in a trusted app
(Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
-
Select network, paste our wallet address.
- Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email
to receive the download link.
Need help? Contact support and we’ll guide you step by step.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
